FLT3 and acute myeloid leukemia: This leads to several important observations: (1) AML blasts in the bone marrow, which are less differentiated, express higher levels of FLT3 and are therefore more resistant to inhibition [98]; and (2) as normal myeloid differentiation naturally downregulates FLT3, differentiation therapy represents a rational complement to FLT3 inhibition.